Dombivli ramp-up weighs on Jupiter Life Line’s Q1 margin
The consolidated operating margin was 5.21 percentage points below the 22-peer healthcare median, while Dombivli added a Rs 9.5 cr initial ramp-up EBITDA loss.
Filed 31 Jul 2026, 18:10 IST · after market close · Jupiter Life Line Hospitals Ltd (JLHL)
Key takeaways
- Jupiter Life Line’s consolidated operating margin was 19.29%, 5.21 percentage points below the 24.5% median for 22 healthcare peers.
- Dombivli’s initial ramp-up EBITDA loss of Rs 9.5 cr and launch-related marketing costs weighed on Q1FY27 operating performance.
- Management said it plans to scale bed capacity from 1,700 to 2,900, with Dombivli commissioning underway and Pune II under construction.
Price around the results
Dombivli launch costs shaped Q1FY27
Jupiter Life Line reported consolidated revenue of Rs 410.98 cr and net profit of Rs 37.51 cr in Q1FY27. Management said Dombivli completed its first full quarter of operations but incurred an initial ramp-up EBITDA loss of Rs 9.5 cr, alongside higher marketing costs from launch activities. Other income of Rs 10.59 cr also made a meaningful contribution relative to profit before tax of Rs 50.55 cr.
Operating margin trails the healthcare peer median
The 19.29% consolidated operating margin was 5.21 percentage points below the 24.5% median for 22 healthcare companies that had reported the quarter. Management attributed the operating pressure to Dombivli’s initial ramp-up loss and launch spending. Below operating profit, it cited higher depreciation after Dombivli’s commercialisation and higher finance costs due to debt raised for ongoing capex.
Expansion pipeline remains the central business focus
Management said Dombivli’s occupancy was increasing steadily, supported by higher patient footfall, expanded clinical services and growing patient acceptance. It said the company is adding specialties, strengthening its consultant base and expanding services at Dombivli, while also initiating insurance empanelment there. Management said Pune II’s planned 500-bed hospital is under construction, while the 300-bed Mira-Bhayandar and 400-bed BKC projects remain at earlier development stages.
Results were filed after market close
The company filed its consolidated Q1FY27 results after market close on 31 July 2026. The stock’s post-results reaction was therefore not yet available to assess against its past results.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹411 cr |
| Other income | ₹11 cr |
| Expenses | ₹332 cr |
| Operating profit | ₹79 cr |
| Operating margin (%) | 19.29% |
| Interest | ₹13 cr |
| Depreciation | ₹26 cr |
| Profit before tax | ₹51 cr |
| Tax | ₹13 cr |
| Net profit | ₹38 cr |
| EPS (₹) | ₹5.72 |
Operating margin of 19.29% compares with a Healthcare sector median of 24.50% across 22 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Dombivli completed its first full quarter of operations, with occupancy increasing steadily.
- Dombivli's occupancy growth was supported by higher patient footfall, expanded clinical services and growing patient acceptance.
Guidance & outlook
- Insurance empanelment is expected to improve patient inflows in the coming quarters.
Expansion
- The company plans to scale bed capacity from 1,700 to 2,900.
- Dombivli is being commissioned in phases, with approximately 200 beds operational and 100 additional beds fit-out complete.
- The Pune II greenfield hospital has a planned capacity of 500 beds and is under construction.
- The Mira-Bhayandar greenfield project has a planned capacity of 300 beds and is at the conceptualisation and planning stage.
- The BKC project has a planned capacity of 400 beds and is in documentation and registration.
New initiatives
- The company has initiated the process of insurance empanelment for Dombivli.
- The company is adding new specialties, strengthening its consultant base and expanding service offerings at Dombivli.
Problems & risks
- Dombivli recorded an initial ramp-up EBITDA loss of Rs 9.5 crore and higher marketing costs from launch activities.
- Depreciation increased following the commercialisation of Dombivli hospital.
- Finance costs increased because of higher debt for ongoing capex.
What to watch
- Whether Dombivli’s initial Rs 9.5 cr EBITDA loss narrows as occupancy increases.
- Whether operating margin moves closer to the 24.5% healthcare peer median.
- Progress toward management’s stated bed-capacity plan of 2,900 beds from 1,700.